Oleno-MD 10 Tablet contains Olanzapine 10 mg, an atypical antipsychotic agent indicated for the treatment of schizophrenia and bipolar disorder. Olanzapine exerts its therapeutic effects primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors in the central nervous system, thereby helping to restore the balance of neurotransmitters implicated in psychotic and mood disorders. Oleno-MD 10 is effective in managing acute and maintenance phases of schizophrenia, reducing hallucinations, delusions, and disorganized thinking. It is also used in the treatment of manic or mixed episodes associated with bipolar I disorder, either as monotherapy or adjunctive therapy with mood stabilizers. The tablet should be administered orally once daily, with or without food, as prescribed by a healthcare professional. Common adverse effects include sedation, weight gain, increased appetite, dry mouth, and extrapyramidal symptoms, though the incidence of movement disorders is generally lower compared to typical antipsychotics. Caution is advised in patients with a history of diabetes, cardiovascular disease, or seizures. Regular monitoring of metabolic parameters and clinical response is recommended during therapy. Oleno-MD 10 should be used under strict medical supervision to optimize therapeutic outcomes and minimize potential risks.